Story Stocks^®

Alcon (ALC) is trading lower following a mixed Q3 report last night. The eye care products maker delivered core EPS of $0.91, modestly exceeding expectations, while revenue grew 4.9% yr/yr to $2.72 bln, roughly in line with estimates. ALC also narrowed its FY26 constant currency revenue growth outlook to approximately 6% from 5-7% and core EPS growth to 12-14% from 12-15%, as it now expects its underlying markets to grow approximately 3%, at the low end of its prior 3-4% range.

• Results were mixed across segments, with Surgical revenue increasing 4% yr/yr to $1.48 bln, slowing from 7% growth in Q2. Implantables declined 2% to $422 mln, while Consumables grew 6% to $789 mln and Equipment/other increased 11% to $269 mln. Vision Care fared better, growing 6% to $1.24 bln, supported by Contact Lenses (+5% cc) and Ocular Health (+8%).
• Implantables remained under pressure from increased competition in the U.S. premium intraocular lens market, with IOL sales declining 1% in constant currency. These challenges have been compounded by sluggish U.S. cataract procedure volumes, partly reflecting surgeon capacity constraints. While PanOptix Pro continues to perform well, its strength has not been enough to fully offset competitive pressures.
• Profitability improved despite slower revenue growth, with core gross margin expanding 280 bps yr/yr to 65.7% and core operating margin increasing 160 bps to 21.8%. However, much of the improvement reflected approximately $60 mln in tariff refunds, alongside manufacturing efficiencies, with roughly two-thirds of the refund being reinvested in the business to support new product launches and commercial initiatives.
• Looking ahead, ALC continues to see opportunities from its pipeline of new products, including Vivity Pro and TruPlus, alongside further contributions from Unity and its expanding dry eye portfolio. However, management expects competitive pressures in premium IOLs to persist into early 2027, while tougher equipment comparisons and subdued cataract procedure volumes remain challenges to stronger growth.

Briefing.com Analyst Insight

The weakness in ALC today appears to reflect continued concerns about its ability to sustain stronger growth amid a challenging cataract market. Recall that competitive pressures in premium IOLs and sluggish U.S. procedure volumes were already weighing on implantables in Q2. Those headwinds persisted in Q3 despite continued strength from PanOptix Pro, with slower underlying market growth and tougher equipment comparisons adding to concerns heading into 2027. Alcon has several upcoming launches, particularly Vivity Pro and TruPlus, offering opportunities to strengthen its competitive position, although a recovery in implantables may take time. Meanwhile, with Q3's margin improvement benefiting significantly from tariff refunds, sustaining underlying profitability as new products ramp will also be important.